[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Seo et al., 2018 - Google Patents

A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots

Seo et al., 2018

View PDF
Document ID
13366111470614467757
Author
Seo J
Al-Hilal T
Jee J
Kim Y
Kim H
Lee B
Kim S
Kim I
Publication year
Publication venue
Nanomedicine: Nanotechnology, Biology and Medicine

External Links

Snippet

The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage that efficiently dissolves the clot without causing systemic fibrinolysis or disrupting …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins

Similar Documents

Publication Publication Date Title
Seo et al. A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
McCarthy et al. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy
Morgan et al. Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage
del Zoppo et al. Thrombolytic intervention in acute thrombotic and embolic stroke
Fanne et al. Blood–brain barrier permeability and tPA-mediated neurotoxicity
EP3395359B1 (en) Plasminogen for use in preventing or treating acute thrombosis and chronic thrombosis
US9644196B2 (en) Plasminogen and plasmin variants
US9314499B2 (en) Annexin A2 and tissue plasminogen activator for treating vascular disease
Gauberti et al. Thrombolytic strategies for ischemic stroke in the thrombectomy era
Pitek et al. Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage
Balami et al. Thrombolytic agents for acute ischaemic stroke treatment: the past, present and future
Saxena et al. Temperature-sensitive liposome-mediated delivery of thrombolytic agents
JP2010502629A (en) Use of tenecteplase to treat acute ischemic stroke
WO2012093132A1 (en) Plasminogen and plasmin variants
Elbayoumi et al. Liposomes for targeted delivery of antithrombotic drugs
Deng et al. Recombinant tissue plasminogen activator-conjugated nanoparticles effectively targets thrombolysis in a rat model of middle cerebral artery occlusion
L Medcalf Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches
Anfray et al. Single-and two-chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke
KR102055390B1 (en) Fusion peptide comprising clot-targeting peptide, ferritin fragment and thrombolytic peptide and its uses
Novokhatny Structure and activity of plasmin and other direct thrombolytic agents
US11261236B2 (en) Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
Louet et al. tPA-NMDAR signaling blockade reduces the incidence of intracerebral aneurysms
Logallo et al. Novel thrombolytics for acute ischemic stroke: challenges and opportunities
Deitcher et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic
Zhang et al. Targeted thrombolysis strategies for neuroprotective effect